Hospices Civils De Lyon

Biomerieux, Inc.

Universite Claude Bernard – Lyon1

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

UniversitÈ Laval

Université Claude Bernard

Université Claude Bernard Lyon I

Bioaster

Julien Textoris

Guillaume Monneret

Manuel Rosa-Calatrava

Fabienne Venet

Elisabeth Cerrato

Benjamin Delwarde

Olivier Terrier

François Mallet

Alexandre Pachot

Estelle Peronnet

Guy Boivin

Jean-Jacques Diaz

Laurence Josset

Marine Mommert

Olivier Tabone

Mario Pizzorno

Virginie Moucadel

Manuel Rosa-calatrava

Thomas Rimmelé

A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.

Kit for assessing the risk of complications in patients with systemic inflammatory response syndrome (SIRS)

A method for determining in vitro or ex vivo the immune status of an individual, preferably a patient, including a step of detecting and/or quantifying the expression of one or more HERV/MaLR sequences in a biological sample of the individual. Also relates to the tools for implementing the method and to the uses thereof.

Method for determining in vitro or ex vivo the immune status of an individual

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Antiviral compositions for treating the flu

The invention concerns a method of in vitro or ex vivo evaluation of the risk of complications in a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, the method being characterized in that it comprises the step of detecting, in a biological sample obtained from said patient, at least one transcript of the IL7R gene, as well as measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene, in a biological sample from a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, in order to evaluate the risk of complications, and in particular of mortality, in said patient. The invention also concerns kits for measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene in a biological sample.

Method for assessing the risk of complications in patients with systemic inflammatory response syndrome (sirs)

Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.

Pharmaceutical or veterinary antiviral compositions

Growing community of inventors

Villeurbanne, France

Julien Textoris